BioCentury | Mar 17, 2011
Distillery Therapeutics

Indication: Cancer

...binding protein 2 (TARBP2) Cell culture and mouse studies suggest that small molecule agonists of TARBP2...
BioCentury | Dec 19, 2005
Clinical News

OxyNal: Phase I data

Data from a U.S. Phase I trial in 16 healthy volunteers showed that when OxyNal was administered in unaltered form, no quantifiable blood levels of naltrexone were released below the level of quantification (LOQ) of...
BioCentury | Jan 17, 2005
Clinical News

Naltrexone neurology data

Data from an open-label, U.S. study in 12 patients comparing naltrexone formulations showed that no quantifiable blood levels of naltrexone were released at a limit of quantification (LOQ) of 7.5 pg/ml, when naltrexone was in...
BioCentury | Jan 17, 2005
Clinical News

Naltrexone neurology data

In an open-label, U.S. study in 12 subjects, food intake did not affect the performance of the formulation and no quantifiable levels of naltrexone were observed at a limit of quantification (LOQ) of 7.5 pg/ml....
BioCentury | Jan 17, 2005
Clinical News

Naltrexone neurology data

Data from an open-label study in 6 subjects showed that no quantifiable blood levels of naltrexone were observed at a limit of quantification (LOQ) of 7.5 pg/ml. The study was designed to observe blood levels...
Items per page:
1 - 5 of 5